Skip to main
NHI

NHI Stock Forecast & Price Target

NHI Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 50%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

National Health Investors is a strong buy due to its positive FFO growth outlook and low-levered balance sheet. The company's healthcare property type diversification, high exposure to private payment for services, and attractive dividend yield, make it a stable investment option. However, there are risks associated with high operator concentration and potential fluctuations in acquisition volumes and asset values. Overall, NHI has robust fundamentals and potential for above-average growth, making it an attractive long-term investment option.

Bears say

National Health Investors is facing several headwinds that could negatively impact its financial performance in the coming years. These include a lower FFO estimate due to gradual redeployment of disposition proceeds and increased leverage, lower than expected occupancy rates in its SHOP segment, and higher transaction costs related to the recent sale of its NHC portfolio. Additionally, the sale of the NHC portfolio, while addressing a long-standing issue, may have not been as advantageous as investors had hoped and may result in lost potential rent increases. Overall, the company's fundamentals and potential growth do not align with its current valuation, making it a negative outlook for the stock.

NHI has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 50% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of National Health Investors and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About National Health Investors (NHI) Forecast

Analysts have given NHI a Buy based on their latest research and market trends.

According to 6 analysts, NHI has a Buy consensus rating as of Jun 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $83.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $83.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

National Health Investors (NHI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.